Characterization of Hematologic Adverse Events and Infections with Mezigdomide, Carfilzomib, and Dexamethasone (Mezikd) in Relapsed/Refractory Multiple Myeloma (RRMM): Phase 3 SUCCESSOR-2 Trial (IMS 2026) - Sep 11, 2026 - Abstract #PA-072; Pres time: Sep 23, 2026; P3 | "Introduction: In the phase 3 SUCCESSOR-2 trial (NCT05552976), MeziKd improved progression-free survival vs Kd (median 18.0 vs 8.3 months) in patients (pts) with RRMM previously treated with anti-CD38 monoclonal antibodies (mAbs) and lenalidomide (LEN). In SUCCESSOR-2, increased neutropenia, thrombocytopenia, and infections observed with MeziKd vs Kd were manageable with standard clinical practice (dose modifications, G-CSF, infection prophylaxis), with low Mezi discontinuation due to these AEs. G-CSF for Gr 3/4 neutropenia was an effective strategy to maintain treatment. MeziKd represents a clinically feasible outpatient treatment option for anti-CD38 mAb- and LEN-exposed RRMM."
Adverse events • P3 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Pneumonia • Respiratory Diseases • Thrombocytopenia
|
|
Fredrik Schjesvold1; Paul G. Richardson2; Chengcheng Fu3; Cesar Augusto Gomez4; Donna Reece5; Gabor Mikala6; Omar Alkharabsheh7; Christopher Parrish8; Kenny Gálvez9; Ridhi Gupta10; Cindy Lee11; Maika Klaiber-Hakimi12; Yok Lam Kwong13; Amitabha Mazumder14; Chandramouli Nagarajan15; Eyck von der Heyde16; Paola Andrea Ochoa17; Armando Santoro18; Angelo Maiolino19; George Zhang20; Soo Jeong Hwang20; Jessica Katz20; Amir Samuel20; Meletios A. Dimopoulos21; Hang Quach22
|